- Home
- SPEGU vs WGSWW Comparison
SPEGU vs WGSWW Comparison
Compare SPEGU & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPEGU
- WGSWW
- Stock Information
- Founded
- SPEGU N/A
- WGSWW 2017
- Country
- SPEGU United States
- WGSWW United States
- Employees
- SPEGU N/A
- WGSWW 1000
- Industry
- SPEGU
- WGSWW Retail: Computer Software & Peripheral Equipment
- Sector
- SPEGU
- WGSWW Technology
- Exchange
- SPEGU Nasdaq
- WGSWW Nasdaq
- Market Cap
- SPEGU N/A
- WGSWW N/A
- IPO Year
- SPEGU 2025
- WGSWW N/A
- Fundamental
- Price
- SPEGU $10.40
- WGSWW $0.07
- Analyst Decision
- SPEGU
- WGSWW
- Analyst Count
- SPEGU 0
- WGSWW 0
- Target Price
- SPEGU N/A
- WGSWW N/A
- AVG Volume (30 Days)
- SPEGU N/A
- WGSWW 36.6K
- Earning Date
- SPEGU N/A
- WGSWW 02-18-2025
- Dividend Yield
- SPEGU N/A
- WGSWW N/A
- EPS Growth
- SPEGU N/A
- WGSWW N/A
- EPS
- SPEGU N/A
- WGSWW N/A
- Revenue
- SPEGU N/A
- WGSWW $305,450,000.00
- Revenue This Year
- SPEGU N/A
- WGSWW N/A
- Revenue Next Year
- SPEGU N/A
- WGSWW N/A
- P/E Ratio
- SPEGU N/A
- WGSWW N/A
- Revenue Growth
- SPEGU N/A
- WGSWW 50.79
- 52 Week Low
- SPEGU N/A
- WGSWW $0.17
- 52 Week High
- SPEGU N/A
- WGSWW $0.21
- Technical
- Relative Strength Index (RSI)
- SPEGU N/A
- WGSWW 38.15
- Support Level
- SPEGU N/A
- WGSWW $0.06
- Resistance Level
- SPEGU N/A
- WGSWW $0.08
- Average True Range (ATR)
- SPEGU 0.00
- WGSWW 0.01
- MACD
- SPEGU 0.00
- WGSWW -0.00
- Stochastic Oscillator
- SPEGU 0.00
- WGSWW 5.80
About SPEGU Silver Pegasus Acquisition Corp Unit
Silver Pegasus Acquisition Corp is a blank check company.
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.